Skip to main content

Menu

BNF for Children April 2026 Update

This update contains 7 significant changes.

Significant Changes:

  • GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases [MHRA/CHM advice] (advice in dulaglutide, liraglutide, semaglutide; see example in dulaglutide).
  • Improving information supplied with Gabapentinoids (pregabalin/gabapentin), Benzodiazepines and Z-drugs [MHRA/CHM advice] (advice in gabapentin, all benzodiazepines; see example in diazepam).
  • Isotretinoin: changes to prescribing guidance and additional risk minimisation measures [MHRA/CHM advice].
  • Omeprazole : new advice in cautions and renal impairment for oral suspension.
  • Semaglutide (Wegovy®, Ozempic®, and Rybelsus®): risk of non-arteritic anterior ischaemic optic neuropathy (NAION) [MHRA/CHM advice].
  • urea (13C): name change to urea (13C).
  • Vitamins: updated guidance for management of vitamin D deficiency.